DNA Ginkgo Bioworks: חוב כולל להון

Governance risks stemming from founder privileges and a cash deficit driven by bioengineering costs are weighing on Ginkgo Bioworks Holdings (DNA). On GURU.Markets, the capital structure ratio (total debt to equity) demonstrates financial stability, where 0.89 records the value of this parameter. The scaling of synthetic biology and AI partnerships in the agricultural sector should reduce losses and accelerate the development of microorganisms.

Ginkgo Bioworks Holdings (DNA) operates as a global synthetic biology operator, creating genetic code for third-party customers. This indicator measures the proportion of borrowed funds relative to equity, determining the business's degree of financial leverage. By analyzing the capital structure—the debt-to-equity ratio—an investor can see the trend of balance sheet recovery. A decrease in this ratio confirms the growth in net asset value. For a platform model, such stability is critical when scaling AI design.